Loading...
  • lipoprotein
  • Atherogenic dyslipidemia in these patients may be caused by a combination of overproduction of very low density lipoprotein (VLDL) apoB-100, decreased catabolism of apoB-containing particles, and increased catabolism of HDL-apoA-I particles. (springer.com)
  • Alterations in the activities of enzymes involved in lipoprotein metabolism, such as cholesteryl ester transfer protein, and the lipoprotein content of lipid particles, along with their glycation and oxidation, play a role in the pathogenesis of diabetic dyslipidaemia. (eurekaselect.com)
  • therapies
  • Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia and includes discussion of future therapies that are currently in late stages of clinical evaluation. (springer.com)
  • ATLANTA, March 12 - Combination therapies in dyslipidemia have two roles -- to lower LDL cholesterol and to achieve non-HDL goals, according to a symposium here. (medpagetoday.com)
  • genetic
  • citation needed] Physicians and basic researchers classify dyslipidemias in two distinct ways: Presentation in the body (including the specific type of lipid that is increased) Underlying cause for the condition (genetic, or secondary to another condition). (wikipedia.org)
  • There are five types of familial dyslipidemia (not including subtypes), and each are classified from both the altered lipid profile and by the genetic abnormality. (wikipedia.org)
  • A study in genetic variants that regulate lipid metabolism and determine the susceptibility to dyslipidemia in Japanese individuals revealed that UBE2Z, together with ZPR1 and Interleukin-6R, may be important loci for hypertriglyceridemia. (wikipedia.org)
  • Symposium
  • Others, whose LDL cholesterol is controlled, will need combination treatments to control other aspects of their dyslipidemia, he told a satellite symposium held in conjunction with the annual meeting of the American College of Cardiology. (medpagetoday.com)
  • Therapy
  • However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. (springer.com)
  • patients
  • In a cohort of 824 new patients referred to a lipid clinic at an academic medical center in the United States, 28 percent had one or more potential causes of secondary dyslipidemia [ 1 ]. (uptodate.com)
  • This article provides a framework for diagnosing and managing dyslipidaemia, with the aim of reducing patients' CVD risk. (bmj.com)
  • treatments
  • Adjunctive pharmacologic treatments, such as HMG-CoA reductase inhibitors, fibric acid derivatives, niacin (nicotinic acid), or fish oils, may often be required to further correct the dyslipidemia. (springer.com)
  • groups
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for dyslipidemia therapeutics in each of the markets covered. (pitchengine.com)
  • management
  • For all the 8MM, the total prevalent cases of dyslipidemia, increased LDLc, and very high TG (=500mg/dL) were segmented by age and sex, which facilitates an understanding of the distribution of disease within the population, and informs strategies to improve the management of disease. (pitchengine.com)